Connect Biopharma is trading at $2.25, up 5.1% in after-hours trading following a modest intraday pullback from recent pre-market strength.
- The move appears driven by thin extended-hours liquidity rather than a clear catalyst, as there are no fresh company-specific headlines, earnings releases, or FDA decisions.
- The price action follows a period of volatility and comes amid a generally mixed broader risk tone in the extended session.